{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:47:41Z","timestamp":1787071661973,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"\n Purpose:<\/jats:title>\n This study aimed to evaluate the efficacy and safety of pilocarpine 1.25% eye drops for improving near vision acuity in presbyopic individuals.<\/jats:p>\n <\/jats:sec>\n \n Design:<\/jats:title>\n Prospective interventional single-arm clinical trial.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This single-arm prospective interventional trial includes 50 presbyopic individuals aged between 40 to 55, administered pilocarpine 1.25% eye drops daily once (9 am, Hour 0) for one month. Visual parameters, including distance corrected near visual acuity (DCNVA), near add power, amplitude of accommodation (AoA), and depth of focus (DoF) along with ocular biometric parameters, were assessed at baseline and after one month at hour 3 (12 noon) and hour 6 (3 pm). Adverse effects were monitored.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n After one month of pilocarpine treatment, a significant improvement was observed in DCNVA (0.64 \u00b1 0.2 to 0.26 \u00b1 0.11,\n P<\/jats:italic>\n < 0.001) along with a decrease in near add power (1.43 \u00b1 0.43 D to 0.42 \u00b1 0.22 D,\n P<\/jats:italic>\n < 0.001). The AoA increased (3.23 \u00b1 0.74 D to 3.92 \u00b1 0.93 D,\n P: 0.005<\/jats:italic>\n ), and DoF widened (0.72 \u00b1 0.18 D to 0.81 \u00b1 0.26 D,\n P: 0.038<\/jats:italic>\n ). No change in ocular biometry parameters was observed. The change in DCNVA showed strong positive correlations with change in near add (\n r<\/jats:italic>\n : 0.84,\n P: <0.001<\/jats:italic>\n ) and AoA (\n r:<\/jats:italic>\n 0.66,\n P: 0.04<\/jats:italic>\n ). Adverse effects were mild and did not lead to discontinuation.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Pilocarpine 1.25% eye drops demonstrated statistically significant improvements in DCNVA, near add, AoA, and DoF after one month of treatment. Pilocarpine 1.25% eye drops shown increase in the AoA and DoF; without any significant change in ocular biometry parameters. The use of pilocarpine 1.25% eye drops can be an alternative intervention for enhancing near vision acuity of presbyopic subjects.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_96_25","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:00:26Z","timestamp":1758801626000},"page":"1486-1490","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pilocarpine 1.25% efficacy for management of uncorrected presbyopia (PILE-UP study)"],"prefix":"10.4103","volume":"73","author":[{"given":"Rohit","family":"Saxena","sequence":"first","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Gupta","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Nidhi","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himani","family":"Thakur","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeewan S","family":"Titiyal","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sharma","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1475-1313.2007.00484.x","article-title":"Age-related changes in static accommodation and accommodative miosis","volume":"27","author":"Radhakrishnan","year":"2007","journal-title":"Ophthalmic Physiol Opt"},{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.ophtha.2018.04.013","article-title":"Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: Systematic review, meta-analysis and modelling","volume":"125","author":"Fricke","year":"2018","journal-title":"Ophthalmology"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archopht.121.11.1577","article-title":"Associations of presbyopia with vision-targeted health-related quality of life","volume":"121","author":"McDonnell","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/opo.12091","article-title":"Developments in the correction of presbyopia I: Spectacle and contact lenses","volume":"34","author":"Charman","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/tjo.tjo_53_18","article-title":"Correction of presbyopia: An integrated update for the practical surgeon","volume":"8","author":"Balgos","year":"2018","journal-title":"Taiwan J Ophthalmol"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcrs.2011.07.027","article-title":"Small aperture corneal inlay for the correction of presbyopia: 3 year follow up","volume":"38","author":"Seyeddain","year":"2012","journal-title":"J Cataract Refract Surg"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preteyeres.2018.09.004","article-title":"Presbyopia: Effectiveness of correction strategies","volume":"68","author":"Wolffsohn","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1046\/j.1532-5415.2002.50502.x","article-title":"Multifocal glasses impair edge-contrast sensitivity and depth perception and increase the risk of falls in older people","volume":"50","author":"Lord","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/APO.0000000000000297","article-title":"A review of pharmacological presbyopia treatment","volume":"9","author":"Grzybowski","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"100065","DOI":"10.1016\/j.xops.2021.100065","article-title":"Combinations of pilocarpine and oxymetazoline for the pharmacological treatment of presbyopia: Two randomized phase 2 studies","volume":"1","author":"Price","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ICU.0000000000000770","article-title":"Pharmacological strategies for treating presbyopia","volume":"32","author":"Betinaa","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2022.0059","article-title":"Safety and efficacy of AGN-190584 in individuals with presbyopia: The GEMINI 1 phase 3 randomized clinical trial","volume":"140","author":"Waring","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0002-9394(14)76701-7","article-title":"The effect of light intensity and dose of dilute pilocarpine eyedrops on pupillary constriction in healthy subjects","volume":"112","author":"Drummond","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1167\/iovs.14-14801","article-title":"Quantitative analysis of functional changes caused by pinhole glasses","volume":"55","author":"Kim","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajo.2023.05.008","article-title":"Safety and efficacy of twice-daily pilocarpine HCl in presbyopia: The virgo phase 3, randomized, double-masked, controlled study","volume":"253","author":"Kannarr","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/ICU.0000000000000864","article-title":"Pilocarpine 1.25% and the changing landscape of presbyopia treatment","volume":"33","author":"Meghpara","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9394(73)90898-2","article-title":"Pilocarpine uptake by pigmented uveal tissue","volume":"75","author":"Lyons","year":"1973","journal-title":"Am J Ophthalmol"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1167\/iovs.10-7108","article-title":"Application of advanced statistics in ophthalmology","volume":"52","author":"Fan","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.exer.2010.02.005","article-title":"Topical and intravenous pilocarpine stimulated accommodation in anesthetized rhesus monkeys","volume":"90","author":"Wendt","year":"2010","journal-title":"Exp Eye Res"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3928\/23258160-20220629-01","article-title":"Vitreofoveal traction associated with pilocarpine for presbyopia","volume":"53","author":"Amarikwa","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajo.2022.05.011","article-title":"Retinal detachments associated with topical pilocarpine use for presbyopia","volume":"242","author":"Al-Khersan","year":"2022","journal-title":"Am J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_96_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:50:37Z","timestamp":1787068237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_96_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_96_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-01-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}